This site uses cookies

ECU Announces New Corporate Sponsor

 

The ECU is very pleased to announce Erchonia® Lasers Limited as Premium Corporate Sponsor.

Based in Melbourne, Florida, family-owned Erchonia® is the global leader in the manufacture and development of low-level laser therapy technology (3LT). It is a characteristically American success story. From humble beginnings in a garage in 1996, Erchonia® today develops and sells advanced, non-invasive 3LT medical equipment in over 50 countries. In 2002 the Food and Drug Administration gave Erchonia® the first low-level laser market clearance, creating a new device category: NHN Biostimulation lasers. Now Erchonia® has 17 different market clearances from the FDA.

ECU President, Vasileios Gkolfinopoulos, welcomed the association with Erchonia® as another step in the journey to put chiropractic at the epicentre of interprofessional care for musculoskeletal health: “We are delighted that Erchonia® will be sponsoring a workshop at the forthcoming ECU2020 convention in Utrecht, to be led by the well-respected Dr Robert Silverman, a graduate of the University of Bridgeport.”

EMEA leader for Erchonia®, Simon Ramshaw, commented: “Erchonia® remains passionately committed to effective, research-based 3LT solutions for a wide variety of conditions — from managing chronic/acute pain/accelerated healing in a variety of medical disciplines to promoting fat loss. Over the last 23 years Erchonia® has been conducting research and development with leading physicians to advance the science and knowledge surrounding low level lasers, elevating us to the heights of global leaders in the field of non-thermal laser health care applications. All Erchonia® lasers have been through rigorous Level One (510k) placebo controlled, double blind, randomised, multi-centre studies prior to market introduction, which have proven them to be safe and effective. We believe in pushing the boundaries and defying the dogma and will continue to do so for the benefit of patients receiving treatments with our lasers.”

Erchonia® research credits include:

Evaluation of Low-Level Laser Therapy at 635nm for the Treatment of Acute and Chronic Neck and Shoulder Pain:  A Placebo-Controlled, Randomized Study
Laser in Surgery Medicine 2014, Volume 46, Number S25, March 2014 Ryan Maloney, Steven Shanks
Phoenix, AZ; Erchonia® Corporation, McKinney, TX

Low-Level Laser Therapy for the Treatment of Chronic Neck and Shoulder Pain
Funct Neurol Rehabil Ergon 2016;6(2):97-104
Gregory C. Roche; Daniel J. Murphy; Trevor S. Berry; Steven Shanks

For more information on Erchonia®, visit www.Erchonia®.com.

Upcoming events more than 2 weeks from now

View all Seminars